Abstract-Endogenous estrogens mediate protective effects in the cardiovascular system, affecting both endotheliumdependent and endothelium-independent mechanisms. Previous studies have suggested that nonselective estrogen receptor agonists such as endogenous estrogens inhibit endothelium-dependent vasoconstriction; however, the role of estrogen receptors in this response has not yet been clarified. This study investigated whether the intracellular transmembrane G protein-coupled estrogen receptor (GPER) regulates vascular reactivity in mice. Effects of chronic deficiency (using mice lacking the GPER gene) and acute inhibition (using the GPER-selective antagonist G15) on endothelium-dependent and endothelium-independent vascular reactivity, and the effects of GPER deficiency on vascular gene expression and structure were investigated. We found that chronic GPER deficiency is associated with increased endothelial prostanoid-mediated vasoconstriction but has no effect on endothelial nitric oxide bioactivity, gene expression of endothelial nitric oxide synthase and thromboxane prostanoid (TP) receptor, or vascular structure. GPER deletion also increases TP receptor-mediated contraction. Acute GPER blockade enhances endothelium-dependent contractions and reduces endothelial nitric oxide bioactivity. Contractions in response to TP receptor activation are unaffected by G15. In conclusion, this study identifies GPER as the first estrogen receptor with inhibitory activity on endothelium-dependent contractility. These findings may be important for understanding and treating diseases associated with increased endothelial vasoconstrictor prostanoid activity such as hypertension and obesity. Key Words: EDCF Ⅲ endothelium Ⅲ estrogen Ⅲ GPER Ⅲ GPR30 Ⅲ cyclooxygenase Ⅲ prostanoid V ascular tone is maintained by a balanced release of endothelial relaxing factors including nitric oxide (NO), and endothelium-derived contracting factors (EDCF) such as prostanoids and endothelin. 1,2 NO is released under basal conditions, in response to shear stress and vasodilators such as acetylcholine. 3 Acetylcholine and other agonists also stimulate the production of EDCF, including cyclooxygenase (COX)-derived prostanoids that activate thromboxane prostanoid (TP) receptors on vascular smooth muscle cells (VSMC). 1,2,4 In arteries of patients with essential hypertension, endothelium-dependent NO bioactivity is impaired, whereas activity of vasoconstrictor prostanoids is increased. 1,2 These abnormalities in endothelial cell function are associated with an increased cardiovascular risk. 5 Endogenous estrogens beneficially modulate the activity of endothelial factors by increasing the transcription of the endothelial NO synthase (eNOS) gene 6 and acutely stimulating NO production through eNOS. 7 Effects of estrogens are mediated by multiple receptors including the classic estrogen receptors ER␣ and ER␤, 8 with NO-dependent effects of estrogens requiring functional ER␣. 7,9 -11 Estrogens also bind to the novel, 7-transmembrane spanning intracellular G protein-coupled estrogen receptor (GPER, previously termed GPR30) 8, 12 cloned from human endothelial cells 13 and expressed throughout the cardiovascular system. 8 The development of the GPER-selective agonist G-1 14 has facilitated studies that demonstrate GPER activation induces acute vasodilation and lowers blood pressure in rodents. [15] [16] [17] [18] [19] Moreover, G-1-dependent relaxation is absent in GPER knockout (GPER 0 ) mice, further corroborating the requirement of this receptor to mediate vascular responses. 15 We 18 and others 17, 19 have shown that acute GPER-mediated vasodilator effects are at least partly endothelium-and NO-dependent.
V ascular tone is maintained by a balanced release of endothelial relaxing factors including nitric oxide (NO), and endothelium-derived contracting factors (EDCF) such as prostanoids and endothelin. 1, 2 NO is released under basal conditions, in response to shear stress and vasodilators such as acetylcholine. 3 Acetylcholine and other agonists also stimulate the production of EDCF, including cyclooxygenase (COX)-derived prostanoids that activate thromboxane prostanoid (TP) receptors on vascular smooth muscle cells (VSMC). 1, 2, 4 In arteries of patients with essential hypertension, endothelium-dependent NO bioactivity is impaired, whereas activity of vasoconstrictor prostanoids is increased. 1, 2 These abnormalities in endothelial cell function are associated with an increased cardiovascular risk. 5 Endogenous estrogens beneficially modulate the activity of endothelial factors by increasing the transcription of the endothelial NO synthase (eNOS) gene 6 and acutely stimulating NO production through eNOS. 7 Effects of estrogens are mediated by multiple receptors including the classic estrogen receptors ER␣ and ER␤, 8 with NO-dependent effects of estrogens requiring functional ER␣. 7,9 -11 Estrogens also bind to the novel, 7-transmembrane spanning intracellular G protein-coupled estrogen receptor (GPER, previously termed GPR30) 8, 12 cloned from human endothelial cells 13 and expressed throughout the cardiovascular system. 8 The development of the GPER-selective agonist G-1 14 has facilitated studies that demonstrate GPER activation induces acute vasodilation and lowers blood pressure in rodents. [15] [16] [17] [18] [19] Moreover, G-1-dependent relaxation is absent in GPER knockout (GPER 0 ) mice, further corroborating the requirement of this receptor to mediate vascular responses. 15 We 18 and others 17, 19 have shown that acute GPER-mediated vasodilator effects are at least partly endothelium-and NO-dependent.
The role of GPER in endothelium-dependent vasoconstriction is unknown. Natural estrogens such as 17␤-estradiol, a nonselective agonist of ER␣, ER␤, and GPER, 8 modulate vasoconstrictor prostanoid activity and the expression of TP receptors and prostanoid synthases. 20 -26 Furthermore, inhibitory effects of 17␤-estradiol on COX-dependent responses to vasoconstrictors have suggested a role of estrogen recep-tors, 27 although the specific estrogen receptor(s) involved in endothelium-dependent vasoconstriction have not been identified. Using GPER 0 mice and the GPER-selective antagonist G15, 28 the present study was therefore designed to test the hypothesis that GPER is involved in endothelium-dependent and -independent regulation of vasomotor tone, with a particular emphasis on endothelial prostanoid-mediated contractions.
Methods

Vascular Function Experiments
Male C57Bl6 and GPER-deficient (GPER 0 ) mice (3 months of age) were anesthetized by intraperitoneal injection of sodium pentobarbital and exsanguinated by cardiac puncture. All procedures were approved by and carried out in accordance with institutional policies and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The aorta was excised and prepared for measurements of isometric force in organ baths as described. 15, 18, 29 To study acute effects of GPER inhibition on vascular function, selected rings were pretreated with the GPER-selective antagonist G15 (3 mol/L) 28 or vehicle (ethanol 0.27%, DMSO 0.03% vol/vol) for 20 minutes. Some rings were also pretreated with the nonselective COX inhibitor indomethacin (10 mol/L), the TP receptor antagonist SQ 29,548 (1 mol/L), or the NO synthase inhibitor L-NAME (300 mol/L) for 30 minutes. Concentration-response curves to acetylcholine (0.1 nmol/L to 100 mol/L), sodium nitroprusside (SNP, 0.01 nmol/L to 10 mol/L), and U46619 (0.1 nmol/L to 10 mol/L) were obtained. Basal NO bioactivity was determined as described. 30 To exclude interference with NO-dependent effects of GPER, [17] [18] [19] responses to SNP and U46619 were recorded in the presence of L-NAME.
Histological Analyses and Immunohistochemistry
Paraffin-embedded cross sections (2 m) of WT and GPER 0 aortas were stained with hematoxylin and eosin using a standard protocol. For immunohistochemical analyses, sections were stained as described, 31 using the following antibodies: ␣-smooth muscle actin (1:200), proliferating cell nuclear antigen (PCNA, 1:500), and Ki-67 (1:100).
Quantitative Real-Time PCR
RNA from thoracic aorta of WT and GPER 0 mice was extracted and reverse transcribed. PCR was performed using TaqMan gene expression assays. Gene expression was calculated using the 2 Ϫ⌬⌬CT method. 32 
Statistical Analyses
Area under the curve (AUC) and EC 50 values (as negative logarithm: pD 2 ) of concentration-response curves were calculated by nonlinear regression analysis. 33 
Results
Effect of GPER Deficiency on Endothelium-Dependent Vascular Reactivity
To assess the effect of endogenous GPER expression on endothelial vasoreactivity, we examined acetylcholineinduced endothelium-dependent relaxation and contraction 34, 35 in the aorta of wild-type (WT) and GPER 0 mice. Endothelium-dependent, receptor-stimulated NO release by acetylcholine induced similar extents of relaxation in phenylephrine-preconstricted rings from WT and GPER 0 mice ( Figure 1A) . However, at acetylcholine concentrations Ն0.1 mol/L, which stimulate the release of EDCF, 21- Figure 1A ). Consistent with an EDCF-mediated response, 1,2 the nonselective COX inhibitor indomethacin and the TP receptor antagonist SQ 29,548 completely blocked contractions to acetylcholine (nϭ4 -5, PϽ0.05 versus untreated vessel rings, Figure 1A ). To assess the role of GPER in EDCF-mediated activation of TP receptor signaling in VSMC, 1,2 we measured concentration-dependent contraction to the selective TP receptor agonist U46619. Contractions to U46619 were increased in GPER 0 aorta (maximal effect, 197Ϯ8% versus 156Ϯ10%; AUC, 586Ϯ22 versus 435Ϯ27 AU; pD 2 , 8.01Ϯ0.03 versus 7.82Ϯ0.12; nϭ5-6, PϽ0.01 versus WT), consistent with an inhibitory effect on prostanoid-mediated VSMC contractility by endogenous GPER in WT mice. TP receptor gene expression was unaffected by GPER deficiency (Table) , which also had no effect on gene expression levels of prostanoid-generating enzymes, including COX-1, prostacyclin synthase, and thromboxane A 2 synthase (Table) .
Chronic and Acute Effects of GPER Inhibition on Endothelial NO and EDCF Activity
Based on previous findings that the GPER-selective agonist G-1 induces endothelium-and NO-dependent relaxation, [17] [18] [19] we next investigated the role of GPER in basal and stimulated bioactivity of NO. GPER deficiency had no effect on receptor-stimulated, NO-mediated relaxation ( Figure 1A ), on basal NO bioactivity (41.9Ϯ9.3% versus 46.0Ϯ9.2%, nϭ6 -9, PϭNS versus WT, Figure 2A ) or on eNOS gene expression (Table) . In contrast, acute inhibition of GPER with the selective antagonist G15 reduced basal NO bioactivity in WT mice (38.3Ϯ5.7% versus 57.7Ϯ5.2%, nϭ4 -6, PϽ0.05 versus vehicle; Figure 2A ). Moreover, receptorstimulated endothelial NO release in response to acetylcholine in WT mice was attenuated by G15 (maximal effect, Ϫ60.7Ϯ3.5% versus Ϫ74.4Ϯ2.5%; AUC, 90Ϯ11 versus 133Ϯ9 AU; nϭ5-6, PϽ0.05 versus vehicle; Figure 2B ). At higher concentrations of acetylcholine, blockade of GPER by G15 yielded an increase in contraction to acetylcholine 21-23,34 -36 (9-fold at 0.1 mmol/L, nϭ5-6, PϽ0.05 versus vehicle; Figure  3A ). In contrast, contraction in response to TP receptor activation by U46619 was unaffected by G15 ( Figure 3B ), compatible with the notion that acute GPER inhibition augments endothelial EDCF activity and/or release but not VSMC TP receptor signaling. In addition, G15 alone had no effect on vascular tone in quiescent aortic rings (data not shown).
Acute and Chronic Effects of GPER Inhibition on Endothelium-Independent Relaxation
Endothelium-independent, NO-mediated relaxation in response to SNP was slightly but significantly enhanced in GPER 0 mice (maximal effect, Ϫ111Ϯ1% versus Ϫ106Ϯ1%, PϽ0.01 versus WT; AUC, 421Ϯ7 versus 402Ϯ7 AU, PϭNS; pD 2 8.84Ϯ0.05 versus 8.82Ϯ0.08, PϭNS; nϭ5-6; Figure 4A ). GPER deficiency had no effect on gene expression levels of the ␣-or ␤-subunits of soluble guanylate cyclase, the downstream target of NO in VSMC 3 (Table) . Moreover, G15 did not acutely affect endothelium-independent relaxation to SNP ( Figure 4B ), suggesting that only the chronic lack of GPER to a very small extent affects smooth muscle sensitivity to NO.
Vascular Histology and Immunohistochemistry
To determine whether the increased vasoconstriction in GPER 0 animals might be associated with structural changes in the vasculature, histological analyses of the aorta were performed. Hematoxylin and eosin staining of aorta cross sections revealed structurally normal vascular walls in WT and GPER 0 animals, with no apparent changes in thickness of the smooth muscle layer ( Figure 5 ). There was also no evidence of changes in VSMC differentiation or proliferation as assessed by staining for ␣-smooth muscle actin ( Figure 5 ), PCNA, and Ki-67 (data not shown).
Discussion
The present study provides evidence that endogenous GPER regulates vascular activity of prostanoid-dependent endothelial vasoconstriction. Chronic deficiency of the GPER gene has no effect on NO bioactivity but is associated with enhanced VSMC contraction to endothelium-dependent, COX-derived vasoconstrictor prostanoids and to direct TP receptor activation. In addition, histological and immunohistochemical analyses revealed structurally normal arteries in GPER 0 mice. By contrast, acute blockade of GPER decreases both basal and stimulated endothelial NO bioactivity and increases EDCF-mediated responses while contractions to a TP receptor agonist remain unchanged. These data identify GPER as a novel, inhibitory regulator of endothelial vasoconstrictor prostanoids and as the first estrogen receptor specifically associated with the regulation of endothelial vasoconstriction. Values are meanϮSEM; nϭ4 -5.
Acetylcholine induces the release of 2 counteracting endothelial mediators in the mouse aorta: NO-mediated relaxation is induced at low concentrations of acetylcholine, whereas a moderate EDCF-mediated contraction is observed at higher concentrations of acetylcholine. 34 In the present study, we demonstrate that GPER deficiency augments acetylcholinemediated contraction, which is completely abolished by either inhibition of COX or TP receptors, consistent with an EDCF-based mechanism. 1,2 Moreover, direct activation of the EDCF-responsive element in VSMC, the TP receptor, reproduced the enhanced constrictor response in the absence of GPER with TP receptor gene expression levels being unaffected. Similar to the present findings, sensitivity to the prostanoid PGH 2 is increased in spontaneously hypertensive rats (SHR) compared with normotensive animals, with no change in TP receptor expression levels in SHR. 36, 37 This suggests that a hyper-responsiveness of VMSC may contribute to endothelium-dependent contractions in both GPER 0 mice and the SHR, 2,36 possibly mediated by either increased calcium influx following TP receptor activation or enhanced sensitivity of contractile proteins. 38 Consistent with this possibility, we recently observed that the calcium sensitivity of VSMC to endothelin-1-mediated constrictions is enhanced in GPER 0 arteries. 39 The present study also shows that endothelium-independent NO-mediated relaxation was slightly increased in GPER 0 vessels with no change in guanylate cyclase gene expression, suggesting the possibility that chronic enhanced sensitivity to endothelium-derived constrictors might be compensated for by enhanced smooth muscle sensitivity to NO.
The enhanced EDCF response in GPER 0 mice is likely unrelated to reduced NO release, 1,2 because GPER deficiency had no effect on basal or stimulated NO bioactivity, or eNOS gene expression. Moreover, GPER deficiency had no effect on the gene expression levels of enzymes involved in prostanoid synthesis, including COX-1, which mediates endotheliumdependent contractions in large murine arteries 35 as well as synthases for thromboxane A 2 and prostacyclin, molecules that function as EDCF under certain conditions. 1,2 It is possible that an increased prostanoid release alone or in conjunction with an exaggerated production of reactive oxygen species, which stimulates formation of vasoconstrictor prostanoids, 1,2 contributes to the enhanced EDCF response in GPER 0 animals. Acute GPER inhibition by G15 reduced endotheliumdependent, receptor-stimulated, and basal NO bioactivity. This is consistent with previous studies demonstrating that stimulation of GPER using the selective agonist G-1 causes acute relaxation that is endothelium-and NO-dependent, [17] [18] [19] and is blocked by G15. 19 In the present study, we also report that at higher concentrations capable of EDCF stimulation, 21-23,34 -36 acetylcholine-mediated endothelium-dependent contractions are strongly augmented in the presence of G15. This may be in part due to the observed G15-dependent reduction of NO bioactivity, which potentiates EDCF-mediated contractions. 1,2 Moreover, the response to VSMC TP receptor activation was unaffected by G15, suggesting no increase in VSMC sensitivity to prostanoids in contrast to our findings in GPER 0 mice. The activity of endothelium-derived vasoconstrictor prostanoids increases with aging and diseases such as hypertension and obesity, conditions associated with structural changes in the vascular wall. 1, 2, 40, 41 In the present study, we used healthy adult mice and found no effect of GPER deficiency on media thickness, differentiation, or proliferation in the smooth muscle layer of the aorta consistent with normal vascular structure. Our results confirm previous findings in adult female GPER 0 mice showing normal structure of the aortic media. 42 In these animals, media thickness of non-pressure-fixed mesenteric arteries was also unaffected by GPER deficiency, whereas the vessel diameter was slightly decreased in 9-month-old GPER 0 compared with WT mice. 42 However, mean arterial blood pressure in anesthetized GPER 0 animals did not increase with age, although the mean arterial blood pressure of GPER 0 mice at 9 months was higher than WT mice of the same age. 42 Whether and to what extent the increased endothelium-dependent vasoreactivity observed in GPER 0 in the present study contributes to blood pressure or structural vascular changes associated with the physiological aging process 40 remains to be determined.
GPER is expressed and functional in the cardiovascular system of both males and females. 15, 17, 42, 43 Similar to the findings of the present study in male GPER 0 mice, the absence of ER␣ or ER␤ adversely affects endotheliumdependent vasoreactivity and blood pressure in male animals as well as in men. 9,44 -46 Thus, estrogen receptors are involved in the regulation of endothelium-derived factors independent of sex. 9 Interestingly, many G protein-coupled receptors display a basal intrinsic activity even in the absence of their ligand that might be sufficient to mediate GPER-dependent vascular effects. 47 Furthermore, the activity of the enzyme aromatase within the vascular wall (where it is localized intracellularly, like GPER, to the endoplasmic reticulum 12, 48 ), mediates local conversion of androgen precursors into the nonselective estrogen receptor agonist 17␤-estradiol, which could yield local concentrations sufficient to activate estrogen receptors. 49 In fact, male mice lacking the enzyme aromatase display impaired endothelium-dependent relaxation. 50 These findings are supported by human studies in men treated with an aromatase inhibitor, which impairs endotheliumdependent, flow-mediated dilation. 51 Furthermore, there is evidence that 17␤-estradiol inhibits endothelium-dependent contractions in salt-sensitive hypertension: in the renal artery, ovary-intact females exhibit much lower EDCF-mediated contractions than males, and these responses are inhibited by acute treatment with 17␤-estradiol only in females. 23 As it is unclear to what degree GPER may have mediated these estrogen-dependent effects, further studies are required to clarify any sex-dependent roles of GPER or other ERs in EDCF or NO bioactivity under healthy conditions and in the presence of disease.
Perspectives
Conditions such as aging, hypertension, and obesity accelerate vascular disease development and are associated with increased endothelium-dependent contractions and reduced NO bioactivity. 1, 2, 41 In this study, we have identified GPER as the first estrogen receptor to specifically regulate endothelial prostanoid vasoconstrictor activity. The ability of endogenous GPER to mitigate endothelium-dependent vasoconstriction and to enhance basal and stimulated endothelial NO bioactivity suggests the therapeutic potential of GPER-selective agonists such as G-1 14 to improve endothelium-dependent vascular dysfunction in conditions associated with increased cardiovascular risk.
Expanded Materials and Methods
Animals
Male C57Bl6 (3 months of age, The Jackson Laboratory, Bar Harbor, ME) and GPER-deficient (GPER 0 ) mice (Proctor & Gamble, Cincinnati, OH, provided by Jan S. Rosenbaum) were housed at the animal research facility of the University of New Mexico Health Sciences Center. GPER 0 mice were bred and genotyped as described, 1 and backcrossed 10 generations onto C57Bl6 mice. Animals were maintained under controlled temperature of 22-23 °C on a 12h light, 12h dark cycle and fed normal chow ad libitum. All procedures were approved by and carried out in accordance with institutional policies and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Isolated Vessel Preparation and Experimental Setup
Animals were anesthetized by intraperitoneal injection of sodium pentobarbital (2.2 mg/g BW) and exsanguinated by cardiac puncture. The aorta was immediately excised and placed in cold (4 °C) physiological Krebs-Ringer bicarbonate solution (composition in mmol/L: NaCl 118.6, KCl 4.7, CaCl 2 2.5, KH 2 PO 4 1.2, MgSO 4 1.2, NaHCO 3 25.1, EDTA CaNa2 0.026, Glucose 10.1; pH 7.4). Vessels were carefully dissected free from adherent connective and adipose tissue, and the lower thoracic and upper abdominal aorta was cut into 2mm long rings of equal diameter. Particular care was taken not to damage the endothelium. Isolated rings were mounted onto two 120 μm tungsten wire hooks, transferred to water-jacketed tissue baths (Radnoti, Monrovia, CA, USA) containing Krebs-Ringer bicarbonate solution (37 °C; pH 7.4; oxygenated with 21% O 2 , 5% CO 2 , and balanced N 2 ), and connected to force transducers (Grass Technologies, West Warwick, RI, USA) as described. [2] [3] [4] After equilibrating for 30 min, rings were progressively stretched to the optimal passive tension for generating force during isometric contraction, which was determined as 1.9-2.0 g in precedent studies. Rings were allowed to equilibrate for another 60 min, and repeatedly exposed to high potassium Krebs-Ringer bicarbonate solution (equimolar substitution of 100 mmol/L potassium for sodium) until a stable response was achieved.
Vascular Function Experiments
When indicated, rings were pretreated with the GPER-selective antagonist G15 (3 μmol/L) 5 or vehicle (final concentration in organ bath: ethanol 0.27%, DMSO 0.03% vol/vol) for 20 min. Concentration-response curves to acetylcholine (0.1 nmol/L -100 μmol/L) or sodium nitroprusside (SNP, 0.01 nmol/L -10 μmol/L) were generated in rings precontracted with phenylephrine. Selected rings were pretreated with the non-selective COX inhibitor indomethacin (10 μmol/L) or the TP receptor antagonist SQ 29,548 (1 μmol/L) for 30 min. In addition, concentration-response curves to U46619 (0.1 nmol/L -10 μmol/L) were obtained. To exclude interference with NO-dependent effects of GPER, 4, 6, 7 responses to SNP and U46619 were recorded after incubation with the NO synthase inhibitor L-NAME (300 μmol/L) for 30 min. Rings that showed less than 70% relaxation to acetylcholine were considered to have a damaged endothelium and were discarded.
Determination of Basal NO Bioactivity
Two adjacent vessel rings, one of them pretreated with L-NAME (300 μmol/L) for 30 min, were exposed to phenylephrine (300 nmol/L). Basal NO bioactivity was calculated as the increase in contraction to phenylephrine in rings treated with L-NAME compared to untreated rings.
Histological Analyses and Immunohistochemistry
Aortas of WT and GPER 0 mice were carefully harvested, fixed in formalin, and embedded in paraffin. Sections (2 μm) were cut and stained with hematoxylin eosin using a standard protocol. For immunohistochemical analyses, aorta cross sections embedded in paraffin were stained as previously described 9 using the following antibodies: α-smooth muscle actin (1:200), proliferating cell nuclear antigen (PCNA, 1:500), and Ki-67 (1:100).
Quantitative Real-time Polymerase Chain Reaction (qPCR)
The thoracic aorta of WT and GPER 0 mice was snap-frozen in liquid nitrogen, disrupted and homogenized using a rotor-stator homogenizer. Total RNA was extracted using the silica-based RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA, USA). RNA (200 ng) was reverse transcribed with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). PCR was performed using TaqMan gene expression assays on a 7500 FAST real-time PCR System (Applied Biosystems, Carlsbad, CA, USA). The sets of primers used for amplification of gene-specific cDNA fragments are given in Table S1 . Gene expression was calculated using the 2 -∆∆C(T) method. 10 GAPDH served as house-keeping control.
Drugs and Antibodies
L-NAME (L-N G -Nitroarginine methyl ester), SQ 29,548, and U46619 were from Cayman Chemical (Ann Arbor, MI, USA). SNP was from MP Biomedicals (Solon, OH, USA). All other drugs were from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions were prepared according to the manufacturer's instructions. G15 was synthesized as described (provided by Jeffrey Arterburn, New Mexico State University, Las Cruces, NM, USA), 5 dissolved in DMSO, and subsequently diluted in ethanol 99% to get a stock solution of 3 mmol/L. If needed, stock solutions were diluted in Krebs-Ringer bicarbonate solution to the required concentration before use. Concentrations are expressed as final molar concentration in the organ chamber. α-Smooth muscle actin and PCNA antibodies were from DAKO Diagnostika (Hamburg, Germany), and Ki-67 antibody from LabVision (Wedel, Germany).
Statistical Analyses
Contraction is given as the percentage of contraction to high potassium Krebs-Ringer bicarbonate solution, and relaxation is expressed as the percentage of precontraction. Area under the curve (AUC) and EC 50 values (as negative logarithm: pD 2 ) were calculated by non-linear regression analysis. 11 Data were analyzed using two-way repeated-measures ANOVA followed by Bonferroni post hoc analysis, the unpaired Student's t-test, or the Mann-Whitney U test where appropriate. Values are shown as means±SEM of independent experiments. A P<0.05 value was considered statistically significant. Table S1 . Sets of primers used for amplification of gene-specific cDNA fragments by qPCR. COX, cyclooxygenase; eNOS, endothelial NO synthase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GCα, guanylate cyclase, α-subunit; GCβ, guanylate cyclase, β-subunit; PGI 2 , prostacyclin; TP receptor, thromboxane prostanoid receptor.
